No results for ‘’
Sun Pharma Advanced Research Company Ltd
₹204.22
(0.83%)
Sun, 14 Jun 2026, 04:19 am
Health Technology
Pharmaceuticals: Major
24.5KSun Pharma Advanced Research Company Enterprise Value (EV)
| Particulars | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 113.91 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Price to book ratio | 0 | 38.86 | 30.51 | 146.12 | 265.18 | 0 | 24.82 | 24.77 | 116.67 | 227.92 | 49.44 | 51.40 | 16.98 | 0 | 0 | 258.46 | 11.36 | 95.47 | 0 |
| Price to sales ratio | 0 | 44.71 | 30.97 | 60.02 | 25.56 | 53.36 | 28.39 | 20.66 | 74.76 | 42.26 | 43.07 | 119.94 | 26.84 | 32.92 | 14.68 | 56.91 | 21.40 | 158.92 | 66.92 |
| Price to cash flow ratio | 0 | 0 | 43.05 | 164.25 | 538.66 | 0 | 0 | 114.37 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Enterprise value | 0 | 1675Cr | 1090Cr | 2062Cr | 1493Cr | 1608Cr | 2455Cr | 3443Cr | 11629Cr | 6858Cr | 7719Cr | 9280Cr | 4698Cr | 2588Cr | 3934Cr | 7878Cr | 4722Cr | 11910Cr | 5070Cr |
| Enterprise value to EBITDA ratio | 0 | 81.59 | 0 | 0 | 0 | 0 | 0 | 101.89 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debt to equity ratio | 0 | 0.01 | 0.05 | 0.15 | 1.17 | 0 | 0.75 | 0.04 | 0.04 | 1.86 | 0.02 | 0.01 | 0.01 | 0 | 0 | 2.54 | 0.03 | 0.49 | 0 |
| Return on equity % | 0 | -10.33 | -22.71 | -86.56 | -86.09 | 0 | -107.55 | 24.48 | -33.06 | -107.93 | -126.60 | -114.41 | -60.48 | -225.08 | 0 | 0 | -81.83 | -121.28 | 0 |
Sun Pharma Advanced Research Company Ltd Enterprise Value
The Sun Pharma Advanced Research Company Ltd Enterprise Value is a key financial metric used by investors to evaluate Sun Pharma Advanced Research Company Ltd's valuation, profitability, and overall financial performance. Tracking the Sun Pharma Advanced Research Company Ltd Enterprise Value helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Sun Pharma Advanced Research Company Ltd (NSE: SPARC, BSE: 532872) is currently trading at ₹204.22, with a market capitalization of ₹6678.65Cr. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Sun Pharma Advanced Research Company Ltd Enterprise Value is essential for fundamental analysis.
Sun Pharma Advanced Research Company Ltd Enterprise Value Current Value
The current Sun Pharma Advanced Research Company Ltd Enterprise Value stands at 5070Cr.
The Sun Pharma Advanced Research Company Ltd Enterprise Value has declined compared to earlier levels, suggesting improved fundamentals or more attractive valuation.
Sun Pharma Advanced Research Company Ltd Enterprise Value Historical Trend
The Sun Pharma Advanced Research Company Ltd Enterprise Value has shown the following historical trend:
- 2024: 5070Cr
- 2023: 11910Cr
- 2022: 4722Cr
- 2021: 7878Cr
- 2020: 3934Cr
The decline in Sun Pharma Advanced Research Company Ltd Enterprise Value indicates improving financial efficiency or better earnings growth.
What Sun Pharma Advanced Research Company Ltd Enterprise Value Indicates for Investors
The Sun Pharma Advanced Research Company Ltd Enterprise Value plays a crucial role in understanding the company's financial health and valuation.
This ratio is an important metric used in fundamental analysis of Sun Pharma Advanced Research Company Ltd.
Sun Pharma Advanced Research Company Ltd Enterprise Value Analysis Summary
The Sun Pharma Advanced Research Company Ltd Enterprise Value remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Sun Pharma Advanced Research Company Ltd Enterprise Value should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Sun Pharma Advanced Research Company Ltd Enterprise Value helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.